Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1983 Jan;15(1):31–36. doi: 10.1111/j.1365-2125.1983.tb01459.x

Cardiovascular effects of indoramin in man—a dose ranging study

D P Nicholls, D W G Harron, R G Shanks
PMCID: PMC1427821  PMID: 6849741

Abstract

1 The effect of single and repeated oral doses of indoramin 25 mg, 50 mg, 100 mg and placebo on arterial pressure and heart rate supine, standing and following immersion of the hand in ice was studied in five normal volunteers.

2 Each study period lasted 4 days. Observations were made before and at 2 and 4 after drug administration on days 1 and 4. On days 2 and 3, the drugs were administered daily, but no observations were made.

3 Indoramin did not change arterial pressure or heart rate in the supine position.

4 Indoramin did not reduce the cold pressor response.

5 Indoramin 25 mg produced small reductions in arterial pressure in the standing position, with no change in heart rate.

6 Indoramin 50 mg reduced systolic arterial pressure in the standing position on day 1 from 106.4 ± 2.6 mm Hg (mean ± s.e. mean) to 88.4 ± 7.4 mm Hg at 2 h (P < 0.05 when compared to placebo) and to 96.8 ± 2.2 mm Hg at 4 h (P < 0.05); diastolic pressure was reduced from 76.4 ± 4.1 mm Hg to 57.2 ± 6.4 mm Hg at 2 h (P < 0.01) and to 64.4 ± 4.3 mm Hg at 4 h (P < 0.05). The reductions in arterial pressure were accompanied by an increase in heart rate from 94.0 ± 4.5 beats min-1 to 102.0 ± 7.0 beats min-1 at 2 h, and to 104.6 ± 8.1 beats min-1 at 4 h (P < 0.05 when compared to placebo, but not when compared to the pre-treatment value). Similar changes were observed on day 4 after 50 mg indoramin, but the maximum reduction in arterial pressure was observed at 2 h on day 1, and 4 h on day 4.

7 Indoramin 100 mg reduced systolic arterial pressure in the standing position on day 1 from 114.0 ± 2.6 mm Hg to 99.2 ± 5.8 mm Hg at 2 h, and to 88.0 ± 5.9 mm Hg at 4 h (P < 0.01); diastolic pressure was reduced from 80.4 ± 3.4 mm Hg to 64.4 ± 3.2 mm Hg at 2 h (P < 0.05), and to 64.0 ± 4.5 mm Hg at 4 h (P < 0.05). The reduction in arterial pressure was accompanied by a small increase in heart rate from 102.2 ± 8.3 beats min-1 to 107.2 ± 12.7 beats min-1 at 2 h (P < 0.05 when compared to placebo, but not when compared to the pre-treatment value); no change in heart rate was observed at 4 h. The changes in arterial pressure and heart rate observed on day 4 after 100 mg indoramin were less than those observed on day 1, but these differences were not significant.

8 Indoramin reduces arterial pressure in normal man, but it is not possible to describe a dose-response relationship for the reduction. The reduction is accompanied by only a small increase in heart rate, possibly due to a direct bradycardic action of indoramin on the heart.

Full text

PDF
31

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Algate D. R., Rashid S., Waterfall J. F. Cardioregulatory properties of indoramin in the rat. J Pharm Pharmacol. 1981 Apr;33(4):236–239. doi: 10.1111/j.2042-7158.1981.tb13765.x. [DOI] [PubMed] [Google Scholar]
  2. Algate D. R., Waterfall J. F. Action of indoramin on pre- and postsynaptic alpha-adrenoceptors in pithed rats. J Pharm Pharmacol. 1978 Oct;30(10):651–652. doi: 10.1111/j.2042-7158.1978.tb13351.x. [DOI] [PubMed] [Google Scholar]
  3. Alps B. J., Borrows E. T., Johnson E. S., Staniforth M. W., Wilson A. B. A comparison of the cardiovascular actions of indoramin, propranolol, lignocaine, and quinidine. Cardiovasc Res. 1972 May;6(3):226–234. doi: 10.1093/cvr/6.3.226. [DOI] [PubMed] [Google Scholar]
  4. Alps B. J., Hill M., Fidler K., Johnson E. S., Wilson A. B. The reversal of experimental cardiac arrhythmias by indoramin (Wy 21901). J Pharm Pharmacol. 1971 Sep;23(9):678–686. doi: 10.1111/j.2042-7158.1971.tb08744.x. [DOI] [PubMed] [Google Scholar]
  5. Alps B. J., Hill M., Johnson E. S., Wilson A. B. Quantitative analysis on isolated organs of the autonomic blocking properties of indoramin hydrochloride (Wy 21901). Br J Pharmacol. 1972 Jan;44(1):52–62. doi: 10.1111/j.1476-5381.1972.tb07237.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Baum T., Shropshire A. T. Central and peripheral contribution to the antihypertensive action of indoramin. Eur J Pharmacol. 1975 May;32(1):30–38. doi: 10.1016/0014-2999(75)90319-2. [DOI] [PubMed] [Google Scholar]
  7. Baum T., Shropshire A. T., Eckfeld D. K., Metz N., Dinish J. L., Peters J. R., Butz F., Gluckman M. I. Studies relating to the antihypertensive and antidysrhythmic action of indoramin. Arch Int Pharmacodyn Ther. 1973 Aug;204(2):390–406. [PubMed] [Google Scholar]
  8. Beaughard M., Ferrier M., Labrid C., Lamar J. C., Leboeuf J., Piris P. Studies on the bradycardia induced by bepridil. Br J Pharmacol. 1982 Feb;75(2):293–300. doi: 10.1111/j.1476-5381.1982.tb08785.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Benfey B. G., Varma D. R. Interactions of sympathomimetic drugs, propranolol and phentolamine, on atrial refractory period and contractility. Br J Pharmacol Chemother. 1967 Aug;30(3):603–611. doi: 10.1111/j.1476-5381.1967.tb02166.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Boakes A. J., Prichard B. N., Teoh P. C. Proceedings: Alpha-adrenoceptor inhibition from indoramin in man. Br J Pharmacol. 1972 Feb;44(2):378P–379P. [PMC free article] [PubMed] [Google Scholar]
  11. Cambridge D., Davey M. J., Massingham R. Prazosin, a selective antagonist of post-synaptic alpha-adrenoceptors [proceedings]. Br J Pharmacol. 1977 Mar;59(3):514P–515P. [PMC free article] [PubMed] [Google Scholar]
  12. Carballo R., Conde L., Lapelle M., Suarez J. The treatment of arterial hypertension with a new alpha-blocker, indoramin. Curr Med Res Opin. 1974;2(8):437–443. doi: 10.1185/03007997409115239. [DOI] [PubMed] [Google Scholar]
  13. Coltart D. J., Meldrum S. J., Royds R. B. Myocardial effects of indoramin hydrochloride, a new hypotensive agent. Br J Pharmacol. 1971 Aug;42(4):664P–665P. [PMC free article] [PubMed] [Google Scholar]
  14. Cosnier D., Duchenne-Marullaz P., Rispat G., Streichenberger G. Cardiovascular pharmacology of bepridil (1[3 isobutoxy 2 (benzylphenyl) amino] propyl pyrrolidine hydrochloride) a new potential anti-anginal compound. Arch Int Pharmacodyn Ther. 1977 Jan;225(1):133–151. [PubMed] [Google Scholar]
  15. Drew G. M. Presynaptic modulation of heart rate responses to cardiac nerve stimulation in pithed rats. J Cardiovasc Pharmacol. 1980 Nov-Dec;2(6):843–856. doi: 10.1097/00005344-198011000-00013. [DOI] [PubMed] [Google Scholar]
  16. FitzGerald G. A., Watkins J., Dollery C. T. Regulation of norepinephrine release by peripheral alpha 2-receptor stimulation. Clin Pharmacol Ther. 1981 Feb;29(2):160–167. doi: 10.1038/clpt.1981.26. [DOI] [PubMed] [Google Scholar]
  17. Garvey H. L. Adrenergic mechanisms in the initiation of cardiac arrhythmias. Arch Int Pharmacodyn Ther. 1969 Dec;182(2):376–390. [PubMed] [Google Scholar]
  18. Govier W. C. Myocardial alpha adrenergic receptors and their role in the production of a positive inotropic effect by sympathomimetic agents. J Pharmacol Exp Ther. 1968 Jan;159(1):82–90. [PubMed] [Google Scholar]
  19. Graham R. M., Pettinger W. A. Effects of prazosin and phentolamine on arterial pressure, heart rate, and renin activity: evidence in the conscious rat for the functional significance of the presynaptic alpha-receptor. J Cardiovasc Pharmacol. 1979 Sep-Oct;1(5):497–502. doi: 10.1097/00005344-197909000-00002. [DOI] [PubMed] [Google Scholar]
  20. Guicheney P., Garay R. P., Levy-Marchal C., Meyer P. Biochemical evidence for presynaptic and postsynaptic alpha-adrenoceptors in rat heart membranes: positive homotropic cooperativity of presynaptic binding. Proc Natl Acad Sci U S A. 1978 Dec;75(12):6285–6289. doi: 10.1073/pnas.75.12.6285. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Gulati K., Srimal R. C., Dhawan B. N. On the mechanisms of hypotensive action of indoramin. Pol J Pharmacol Pharm. 1978 Nov-Dec;30(6):811–818. [PubMed] [Google Scholar]
  22. James T. N., Bear E. S., Lang K. F., Green E. W. Evidence for adrenergic alpha receptor depressant activity in the heart. Am J Physiol. 1968 Dec;215(6):1366–1375. doi: 10.1152/ajplegacy.1968.215.6.1366. [DOI] [PubMed] [Google Scholar]
  23. Jones B. R., Gordon C. S., Umans J., Reidenberg M. M., Young C. W. Kinetics of metoprine, a lipid-soluble antifolate. Br J Clin Pharmacol. 1981 Nov;12(5):675–680. doi: 10.1111/j.1365-2125.1981.tb01288.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Kobinger W., Lillie C., Pichler L. N-Allyl-derivative of clonidine, a substance with specific bradycardic action at a cardiac site. Naunyn Schmiedebergs Arch Pharmacol. 1979 Apr;306(3):255–262. doi: 10.1007/BF00507111. [DOI] [PubMed] [Google Scholar]
  25. Koch-Weser J. Medical intelligence drug therapy. N Engl J Med. 1976 Aug 5;295(6):320–323. doi: 10.1056/NEJM197608052950606. [DOI] [PubMed] [Google Scholar]
  26. Kramer R., Rosendorff C., Bloom D. Clinical evaluation of indoramin as the sole agent for the treatment of hypertension. S Afr Med J. 1974 Aug 3;48(37):1569–1572. [PubMed] [Google Scholar]
  27. Langer S. Z. Sixth gaddum memorial lecture, National Institute for Medical Research, Mill Hill, January 1977. Presynaptic receptors and their role in the regulation of transmitter release. Br J Pharmacol. 1977 Aug;60(4):481–497. doi: 10.1111/j.1476-5381.1977.tb07526.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Maconochie J. G., Richards D. A., Woodings E. P. Modification of pressor responses induced by 'cold' [proceedings]. Br J Clin Pharmacol. 1977 Jun;4(3):389P–389P. [PubMed] [Google Scholar]
  29. Millar J. S., Williams E. M. Anion antagonism--a fifth class of antiarrhythmic action? Lancet. 1981 Jun 13;1(8233):1291–1293. doi: 10.1016/s0140-6736(81)92462-4. [DOI] [PubMed] [Google Scholar]
  30. Oates H. F., Graham R. M., Stokes G. S. Mechanism of the hypotensive action of prazosin. Arch Int Pharmacodyn Ther. 1977 May;227(1):41–48. [PubMed] [Google Scholar]
  31. Pitterman A. B., Rollins D. E., Shen D. D., Hurwitz A., Hassanein K. M. Alpha adrenoceptor blockade with oral prazosin. Clin Pharmacol Ther. 1981 Feb;29(2):143–148. doi: 10.1038/clpt.1981.23. [DOI] [PubMed] [Google Scholar]
  32. Rhodes K. F., Waterfall J. F. Pre- and postsynaptic alpha-adrenoceptor antagonism by indoramin in isolated tissues of the rat. J Pharm Pharmacol. 1978 Aug;30(8):516–517. doi: 10.1111/j.2042-7158.1978.tb13308.x. [DOI] [PubMed] [Google Scholar]
  33. Richards D. A., Woodings E. P., Prichard B. N. Circulatory and alpha-adrenoceptor blocking effects of phentolamine. Br J Clin Pharmacol. 1978 Jun;5(6):507–513. doi: 10.1111/j.1365-2125.1978.tb01665.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Royds R. B., Coltart D. J., Lockhart J. D. Pharmacologic studies of indoramin in man. Clin Pharmacol Ther. 1972 May-Jun;13(3):380–392. doi: 10.1002/cpt1972133380. [DOI] [PubMed] [Google Scholar]
  35. Schümann H. J., Wagner J., Knorr A., Reidemeister J. C., Sadony V., Schramm G. Demonstration in human atrial preparations of alpha-adrenoceptors mediating positive inotropic effects. Naunyn Schmiedebergs Arch Pharmacol. 1978 May;302(3):333–336. doi: 10.1007/BF00508304. [DOI] [PubMed] [Google Scholar]
  36. TAYLOR S. H., SUTHERLAND G. R., MACKENZIE G. J., STAUNTON H. P., DONALD K. W. THE CIRCULATORY EFFECTS OF INTRAVENOUS PHENTOLAMINE IN MAN. Circulation. 1965 May;31:741–754. doi: 10.1161/01.cir.31.5.741. [DOI] [PubMed] [Google Scholar]
  37. Wenzel D. G., Su J. L. Interactions between sympathomimetic amines and blocking agents on the rat ventricle strip. Arch Int Pharmacodyn Ther. 1966 Apr;160(2):379–389. [PubMed] [Google Scholar]
  38. Wright B. M., Dore C. F. A random-zero sphygmomanometer. Lancet. 1970 Feb 14;1(7642):337–338. doi: 10.1016/s0140-6736(70)90709-9. [DOI] [PubMed] [Google Scholar]
  39. Yamaguchi N., de Champlain J., Nadeau R. A. Regulation of norepinephrine release from cardiac sympathetic fibers in the dog by presynaptic alpha- and beta-receptors. Circ Res. 1977 Jul;41(1):108–117. doi: 10.1161/01.res.41.1.108. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES